Daily as of 3 Nov 16:00 ET
- Price
- above both $55.52 vs 50 $38.00 / 200 $30.73
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross 26 Aug 2026 · projected 19 bars out
GMAB | Genmab A/S ADSNASDAQADR golden cross and death cross projections, cross tests and history
$55.52
+$0.60 (+1.09%)
Genmab A/S ADS (GMAB) is a NASDAQ-listed ADR that Cruxta has tracked for 50/200 crosses since 2021.
The 50 SMA has sat above the 200 on the daily since Aug 2026, with no cross projected inside the 30 bars Cruxta tracks. Price sits above the 50 and the 200 on the daily, the weekly and the 4-hour.
Timeframe summary
Weekly as of 30 Oct 16:00 ET
- Price
- above both $57.06 vs 50 $30.91 / 200 $29.63
- Projection
- No cross projected
- Test
- Cross test window open, no test bar yet
- Last cross
- 🟨Golden cross week of 21 Sep 2026 · projected 13 bars out
4-hour as of 3 Nov 13:30 ET
- Price
- above both $55.38 vs 50 $41.49 / 200 $33.28
- Projection
- No cross projected
- Test
- No active test
- Last cross
- 🟨Golden cross 16 Jul 2026 · projected 21 bars out
Cross history
| Crossed | Direction | Timeframe | Projected | Cross test |
|---|---|---|---|---|
| week of 21 Sep 2026 | 🟨Golden moderate | weekly | 13 bars out | Active Cross Test |
| 26 Aug 2026 | 🟨Golden steep | daily | 19 bars out | Not tested |
| 16 Jul 2026 | 🟨Golden | 4-hour | 21 bars out | Not tested |
| 14 Apr 2026 | 💀Death steep | daily | 28 bars out | 4 bar cross test |
| 24 Feb 2026 | 💀Death | 4-hour | 22 bars out | Not tested |
About GMAB
ExchangeNASDAQ
InstrumentADR
Median $ volume, 60 d$106M
4-hour coverageYes, since Oct 2025
History on recordSince 2021
Cap bandlarge